{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:19:32Z","timestamp":1790734772821,"version":"4.1.0"},"reference-count":27,"publisher":"Japanese Circulation Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2025,12,25]]},"DOI":"10.1253\/circj.cj-25-0169","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:07:16Z","timestamp":1753222036000},"page":"38-46","source":"Crossref","is-referenced-by-count":4,"title":["Impact of Metabolic Dysfunction-Associated Fatty Liver Disease on Atrial Fibrillation Recurrence After Ablation\u3000\u2015 A Retrospective Study in Japanese Patients \u2015"],"prefix":"10.1253","volume":"90","author":[{"given":"Aiko","family":"Takami","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine and Endocrinology and Metabolism, Faculty of Medicine, Tottori University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine and Endocrinology and Metabolism, Faculty of Medicine, Tottori University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Kotake","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine and Endocrinology and Metabolism, Faculty of Medicine, Tottori University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Okamura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine and Endocrinology and Metabolism, Faculty of Medicine, Tottori University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Tomomori","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine and Endocrinology and Metabolism, Faculty of Medicine, Tottori University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Kawatani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine and Endocrinology and Metabolism, Faculty of Medicine, Tottori University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiyasu","family":"Hirano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine and Endocrinology and Metabolism, Faculty of Medicine, Tottori University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine and Endocrinology and Metabolism, Faculty of Medicine, Tottori University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: A Global Burden of Disease 2010 Study. <i>Circulation<\/i> 2014; 129: 837\u2013847, doi:10.1161\/circulationaha.113.005119.","DOI":"10.1161\/CIRCULATIONAHA.113.005119"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. <i>Nat Rev Cardiol<\/i> 2014; 11: 639\u2013654, doi:10.1038\/nrcardio.2014.118.","DOI":"10.1038\/nrcardio.2014.118"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Iwasaki YK, Noda T, Akao M, Fujino T, Hirano T, Inoue K, et al. JCS\/JHRS 2024 guideline focused update on management of cardiac arrhythmias. <i>Circ J<\/i> 2025; 89: 1012\u20131073, doi:10.1253\/circj.CJ-24-0073.","DOI":"10.1253\/circj.CJ-24-0073"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: The ARREST-AF cohort study. <i>J Am Coll Cardiol<\/i> 2014; 64: 2222\u20132231, doi:10.1016\/j.jacc.2014.09.028.","DOI":"10.1016\/j.jacc.2014.09.028"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Zhou Y, Yan M, Yuan J, Wang Y, Qiao S. Continuous positive airway pressure treatment decreases the risk of atrial fibrillation recurrence in patients with obstructive sleep apnea after radiofrequency ablation. <i>Int Heart J<\/i> 2022; 63: 716\u2013721, doi:10.1536\/ihj.22-129.","DOI":"10.1536\/ihj.22-129"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol<\/i> 2019; 74: 104\u2013132, doi:10.1016\/j.jacc.2019.01.011.","DOI":"10.1016\/j.jacc.2019.01.011"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. <i>Eur Heart J<\/i> 2021; 42: 373\u2013498, doi:10.1093\/eurheartj\/ehaa612.","DOI":"10.1093\/eurheartj\/ehaa612"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Vargas M, Cardoso Toniasso SC, Riedel PG, Baldin CP, Dos Reis FL, Pereira RM, et al. Metabolic disease and the liver: A review. <i>World J Hepatol<\/i> 2024; 16: 33\u201340, doi:10.4254\/wjh.v16.i1.33.","DOI":"10.4254\/wjh.v16.i1.33"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. K\u00e4r\u00e4j\u00e4m\u00e4ki AJ, Hukkanen J, Ukkola O. The association of non-alcoholic fatty liver disease and atrial fibrillation: A review. <i>Ann Med<\/i> 2018; 50: 371\u2013380, doi:10.1080\/07853890.2018.1492147.","DOI":"10.1080\/07853890.2018.1492147"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Donnellan E, Cotter TG, Wazni OM, Elshazly MB, Kochar A, Wilner B, et al. Impact of nonalcoholic fatty liver disease on arrhythmia recurrence following atrial fibrillation ablation. <i>JACC Clin Electrophysiol<\/i> 2020; 6: 1278\u20131287, doi:10.1016\/j.jacep.2020.05.023.","DOI":"10.1016\/j.jacep.2020.05.023"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Kawaguchi T, Sumida Y, Umemura A, Matsuo K, Takahashi M, Takamura T, et al. Genetic polymorphisms of the human <i>PNPLA3<\/i> gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. <i>PLoS One<\/i> 2012; 7: e38322, doi:10.1371\/journal.pone.0038322.","DOI":"10.1371\/journal.pone.0038322"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Li Q, Dhyani M, Grajo JR, Sirlin C, Samir AE. Current status of imaging in nonalcoholic fatty liver disease. <i>World J Hepatol<\/i> 2018; 10: 530\u2013542, doi:10.4254\/wjh.v10.i8.530.","DOI":"10.4254\/wjh.v10.i8.530"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Ikeda S, Sugihara T, Hoshino Y, Matsuki Y, Nagahara T, Okano JI, et al. Pemafibrate dramatically ameliorated the values of liver function tests and fibrosis marker in patients with non-alcoholic fatty liver disease. <i>Yonago Acta Med<\/i> 2020; 63: 188\u2013197, doi:10.33160\/yam.2020.08.009.","DOI":"10.33160\/yam.2020.08.009"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Takami A, Miake J, Kato M, Ogura K, Okamura A, Tomomori T, et al. Impact of BMI and type of ablation procedure on atrial fibrillation recurrence in Japanese patients. <i>J Asian Pac Soc Cardiol<\/i> 2022; 1: e15, doi:org\/10.15420\/japsc.2021.27.","DOI":"10.15420\/japsc.2021.27"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Jin JL, Zhang HW, Cao YX, Liu HH, Hua Q, Li YF, et al. Liver fibrosis scores and coronary atherosclerosis: Novel findings in patients with stable coronary artery disease. <i>Hepatol Int<\/i> 2021; 15: 413\u2013423, doi:10.1007\/s12072-021-10167-w.","DOI":"10.1007\/s12072-021-10167-w"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. <i>Diabetologia<\/i> 1985; 28: 412\u2013419, doi:10.1007\/bf00280883.","DOI":"10.1007\/BF00280883"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Sangro P, de la Torre Al\u00e1ez M, Sangro B, D\u2019Avola D. Metabolic dysfunction-associated fatty liver disease (MAFLD): An update of the recent advances in pharmacological treatment. <i>J Physiol Biochem<\/i> 2023; 79: 869\u2013879, doi:10.1007\/s13105-023-00954-4.","DOI":"10.1007\/s13105-023-00954-4"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Chang CJ, Wu CH, Chang CS, Yao WJ, Yang YC, Wu JS, et al. Low body mass index but high percent body fat in Taiwanese subjects: Implications of obesity cutoffs. <i>Int J Obes Relat Metab Disord<\/i> 2003; 27: 253\u2013259, doi:10.1038\/sj.ijo.802197.","DOI":"10.1038\/sj.ijo.802197"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Wijarnpreecha K, Boonpheng B, Thongprayoon C, Jaruvongvanich V, Ungprasert P. The association between non-alcoholic fatty liver disease and atrial fibrillation: A meta-analysis. <i>Clin Res Hepatol Gastroenterol<\/i> 2017; 41: 525\u2013532, doi:10.1016\/j.clinre.2017.08.001.","DOI":"10.1016\/j.clinre.2017.08.001"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Arafa A, Kokubo Y, Kashima R, Matsumoto C, Teramoto M, Kusano K. Fatty liver index and the risk of atrial fibrillation in a general Japanese population: The Suita study. <i>Circ J<\/i> 2023; 87: 1836\u20131841, doi:10.1253\/circj.CJ-23-0464.","DOI":"10.1253\/circj.CJ-23-0464"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Iwawaki T, Morishima I, Kanzaki Y, Morita Y, Watanabe N, Yoshioka N, et al. Elevated liver fibrosis-4 index predicts recurrence after catheter ablation for atrial fibrillation in patients with heart failure. <i>J Interv Card Electrophysiol<\/i> 2024; 67: 1093\u20131108, doi:10.1007\/s10840-023-01661-2.","DOI":"10.1007\/s10840-023-01661-2"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Yamada S, Kaneshiro T, Nodera M, Amami K, Nehashi T, Oikawa M, et al. Associations of the fibrosis-4 index with left atrial low-voltage areas and arrhythmia recurrence after catheter ablation: Cardio-hepatic interaction in patients with atrial fibrillation. <i>J Arrhythm<\/i> 2024; 40: 585\u2013593, doi:10.1002\/joa3.13045.","DOI":"10.1002\/joa3.13045"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Hijioka N, Kamioka M, Matsumoto Y, Nodera M, Yamada S, Kaneshiro T, et al. Clinical impact of insulin resistance on pulmonary vein isolation outcome in patients with paroxysmal atrial fibrillation. <i>J Cardiovasc Electrophysiol<\/i> 2019; 30: 479\u2013486, doi:10.1111\/jce.13827.","DOI":"10.1111\/jce.13827"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. <i>N Engl J Med<\/i> 2010; 363: 1341\u20131350, doi:10.1056\/NEJMra0912063.","DOI":"10.1056\/NEJMra0912063"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Ren J, Wang X, Yee C, Gorrell MD, McLennan SV, Twigg SM. Sitagliptin is more effective than gliclazide in preventing pro-fibrotic and pro-inflammatory changes in a rodent model of diet-induced non-alcoholic fatty liver disease. <i>Molecules<\/i> 2022; 27: 727, doi:10.3390\/molecules27030727.","DOI":"10.3390\/molecules27030727"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Wu L, Li Z, Xu L, Fan Y, Mao D, Sun H, et al. Nrf2 ameliorates atrial fibrosis during antithrombotic therapy for atrial fibrillation by modulating CYP2C9 activity. <i>J Cardiovasc Pharmacol<\/i> 2024; 84: 440\u2013450, doi:10.1097\/fjc.0000000000001618.","DOI":"10.1097\/FJC.0000000000001618"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Tokushige K, Ikejima K, Ono M, Eguchi Y, Kamada Y, Itoh Y, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020. <i>J Gastroenterol<\/i> 2021; 56: 951\u2013963, doi:10.1007\/s00535-021-01796-x.","DOI":"10.1007\/s00535-021-01796-x"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/90\/1\/90_CJ-25-0169\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T03:18:23Z","timestamp":1766805503000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/90\/1\/90_CJ-25-0169\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,25]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-25-0169","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,25]]},"article-number":"CJ-25-0169"}}